Bigmurph6
Banned
Enobosarm (Ostarine, GTX-024, MK-2866,S-22)
Description
Enobosarm is a second generation Selective Androgen Receptor Modulator (SARM). Though non-steroidal in structure, this drug is closely related anabolic/androgenic steroids in its activity. Enobosarm selectively activates the cellular androgen receptor (AR) in certain tissues, most notably skeletal muscle and bone.
Here it supports constructive metabolism (anabolism). It is also believed to support satellite cell cycle activation, possibly outside of traditional AR binding. Enobosarm is far less active in “androgenic” tissues such as the prostate and sex organs, however, which gives it a distinct separation of anabolic and androgenic effect. This drug is widely used in the sports community for muscle gain and fat loss, typically as an alternative to anabolic steroids.
Enobosarm has been the most extensively studied drug of the SARM class to date. As of 2017, it has been the subject of 24 completed or ongoing human clinical trials, involving more than 1,500 participants in total. It has been under
investigation in several different areas of therapy, including the treatment of cancer cachexia (muscle wasting), breast cancer, and stress urinary incontinence. To many in the
fitness community, this has provided some sense of stability and safety as compared to many other new drugs of the SARM and peptides categories, which in many cases are devoid of human studies.
Thus far, enobosarm has established a consistent record of efficacy as an anabolic agent For example, in one study day for 12 weeks resulted in a significant 3% increase in with healthy elderly men and women, a dose of 3 mg per LBM (41.3 kg; 2.9 lbs.). There was also a significant reduction in fat mass of 6 kg. Physical function, as measured by stair climb power, was significantly improved(415%) as well. With regard to its metabolic effects, enobosarm lowered resting serum glucose levels. This reflected improved insulin sensitivity. Another 12 week study in postmenopausal women reported a similar gain of 1.5 kg of LBM with 3 mg daily3 Again, performance significantly improved as well. In this case, leg press strength increased by 22 lbs.
At an anabolic effective dose (3 mg/daily) enobosarm does not produce notable androgenic side effects. The prostate is not appreciably stimulated in men, nor are virilizing effects apparent in women. It also has minimal effect on serum free testosterone, dihydrotestosterone, estradiol (estrogen), follicle stimulating hormone (FSH), and luteinizing hormone (LH). In some patients, however, enobosarm did produce certain side effects commonly associated with oral anabolic steroid use. This includes mild elevations in liver enzymes, and negative alterations in serum lipids (see: Side Effects). Higher doses are likely to exacerbate some of these side effects. Likewise, enobosarm may appear “mild” at this time, but is not entirely devoid of “steroid-related” risk.
Description
Enobosarm is a second generation Selective Androgen Receptor Modulator (SARM). Though non-steroidal in structure, this drug is closely related anabolic/androgenic steroids in its activity. Enobosarm selectively activates the cellular androgen receptor (AR) in certain tissues, most notably skeletal muscle and bone.
Here it supports constructive metabolism (anabolism). It is also believed to support satellite cell cycle activation, possibly outside of traditional AR binding. Enobosarm is far less active in “androgenic” tissues such as the prostate and sex organs, however, which gives it a distinct separation of anabolic and androgenic effect. This drug is widely used in the sports community for muscle gain and fat loss, typically as an alternative to anabolic steroids.
Enobosarm has been the most extensively studied drug of the SARM class to date. As of 2017, it has been the subject of 24 completed or ongoing human clinical trials, involving more than 1,500 participants in total. It has been under
investigation in several different areas of therapy, including the treatment of cancer cachexia (muscle wasting), breast cancer, and stress urinary incontinence. To many in the
fitness community, this has provided some sense of stability and safety as compared to many other new drugs of the SARM and peptides categories, which in many cases are devoid of human studies.
Thus far, enobosarm has established a consistent record of efficacy as an anabolic agent For example, in one study day for 12 weeks resulted in a significant 3% increase in with healthy elderly men and women, a dose of 3 mg per LBM (41.3 kg; 2.9 lbs.). There was also a significant reduction in fat mass of 6 kg. Physical function, as measured by stair climb power, was significantly improved(415%) as well. With regard to its metabolic effects, enobosarm lowered resting serum glucose levels. This reflected improved insulin sensitivity. Another 12 week study in postmenopausal women reported a similar gain of 1.5 kg of LBM with 3 mg daily3 Again, performance significantly improved as well. In this case, leg press strength increased by 22 lbs.
At an anabolic effective dose (3 mg/daily) enobosarm does not produce notable androgenic side effects. The prostate is not appreciably stimulated in men, nor are virilizing effects apparent in women. It also has minimal effect on serum free testosterone, dihydrotestosterone, estradiol (estrogen), follicle stimulating hormone (FSH), and luteinizing hormone (LH). In some patients, however, enobosarm did produce certain side effects commonly associated with oral anabolic steroid use. This includes mild elevations in liver enzymes, and negative alterations in serum lipids (see: Side Effects). Higher doses are likely to exacerbate some of these side effects. Likewise, enobosarm may appear “mild” at this time, but is not entirely devoid of “steroid-related” risk.
